Syndax Pharmaceuticals, Inc. (SNDX) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to the Syndex second quarter 2025 earnings conference call. Today's call is being recorded. If you would like to ask a question following the company's prepared remarks, please press star five during the call. At this time, I would like to turn the call over to Sharon Clarie, head of investor relations at Syndex Pharmaceuticals. Thank you, Operator. Welcome, and thank you all for joining us today for a review of CINDAS' second quarter 2025 financial and operating results. I'm Sharon Clary, and with me today to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer, Steve Kloster, Chief Commercial Officer, Dr. Nick Botwood, Head of R&D and Chief Medical Officer, Keith Goldan, Chief Financial Officer. Also joining us on the call today for question and answer session are Dr. Peter Ardentlich, Chief Scientific Officer, and Dr. Angela Ganguly, Chief Strategy Officer. This call is accompanied by a slide deck that has been posted on the investor page of the company's website. You can now turn to our forward-looking statements on slide two. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by the statements as a result of various important factors, including those discussed in the risk factor section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements may represent our views as of today, August 4th, 2025 only. A replay of this call will be available on the company'...